Intellia Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 8 →Insiders1 insider bought $1.4M in 1 open-market buy. 7 insiders sold $2.1M, 6 of 17 sales on a 10b5-1 plan.→HoldersARK 12.1%BlackRock 11.0%State Street 6.6%→Financing →PeersClosest companies: MGX, DTIL, PASG→
From the filings
Figures
- Revenue
- $59.5Mlast 12 months
- Net income
- −$400.0Mlast 12 months
- Operating cash flow
- −$363.2Mlast 12 months
- Cash and equivalents
- $106.1Mat the last balance sheet
- Shares outstanding
- 140.0M shareson issue